Cargando…

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with different clinical characteristics and outcome to EGFR-wild-type patients. In these patients, the treatment of choice a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazza, Valentina, Cappuzzo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536882/
https://www.ncbi.nlm.nih.gov/pubmed/28794650
http://dx.doi.org/10.2147/TACG.S103471

Ejemplares similares